Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Operating Leases (2020 - 2025)

Lyell Immunopharma's Operating Leases history spans 6 years, with the latest figure at $44.3 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 24.4% year-over-year to $44.3 million; the TTM value through Sep 2025 reached $44.3 million, down 24.4%, while the annual FY2024 figure was $51.0 million, 10.37% down from the prior year.
  • Operating Leases for Q3 2025 was $44.3 million at Lyell Immunopharma, down from $55.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $67.6 million in Q2 2022 and bottomed at $44.3 million in Q3 2025.
  • The 5-year median for Operating Leases is $62.5 million (2022), against an average of $61.1 million.
  • The largest annual shift saw Operating Leases soared 30.8% in 2021 before it decreased 24.4% in 2025.
  • A 5-year view of Operating Leases shows it stood at $66.6 million in 2021, then fell by 5.22% to $63.2 million in 2022, then dropped by 9.93% to $56.9 million in 2023, then dropped by 10.37% to $51.0 million in 2024, then dropped by 13.16% to $44.3 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Operating Leases are $44.3 million (Q3 2025), $55.1 million (Q2 2025), and $57.1 million (Q1 2025).